Taysha Gene Therapies/$TSHA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Taysha Gene Therapies

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Ticker

$TSHA
Primary listing

Industry

Biotechnology

Employees

73

ISIN

US8776191061

TSHA Metrics

BasicAdvanced
$552M
-
-$0.33
1.02
-

What the Analysts think about TSHA

Analyst ratings (Buy, Hold, Sell) for Taysha Gene Therapies stock.

Bulls say / Bears say

Taysha Gene Therapies has secured a strategic investment of $50 million from Astellas Pharma, acquiring 15% of the company and exclusive options to license TSHA-102 for Rett syndrome and TSHA-120 for giant axonal neuropathy, indicating strong industry confidence in Taysha's pipeline. (tayshagtx.com)
The appointment of Sean P. Nolan, former CEO of AveXis, as Taysha's new CEO brings experienced leadership in gene therapy commercialization, potentially accelerating the development and market entry of Taysha's therapies. (dallasinnovates.com)
Taysha's lead program, TSHA-102 for Rett syndrome, has received multiple regulatory designations, including Regenerative Medicine Advanced Therapy and Fast Track from the FDA, which could expedite its development and approval process. (tayshagtx.com)
Despite a reduction in net loss, Taysha reported a net loss of $89.3 million for the full year ended December 31, 2024, indicating ongoing financial challenges. (tayshagtx.com)
The gene therapy sector faces significant regulatory hurdles and competition, which could delay Taysha's product approvals and market entry, impacting revenue generation. (tayshagtx.com)
Taysha's reliance on partnerships, such as the one with Astellas, may lead to potential dilution of control over its key assets and future revenues. (tayshagtx.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2025.

TSHA Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

TSHA Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $TSHA

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs